United States News Todas as matérias

The Travelers Companies (NYSE:TRV) reported Q2 net income of $2.208 billion, or $10.26 per diluted share, as underwriting results improved.

Amneal Pharmaceuticals (NASDAQ:AMRX) received FDA approval for four additional iohexol presentations targeting a U.S. market with approximately $706 million in annual sales.

Westamerica Bancorporation (NASDAQ:WABC) reported second-quarter net income of $27.4 million and diluted EPS of $1.17, compared with $1.13 in Q1.

Apple (NASDAQ:AAPL) received approval from the Cyberspace Administration of China to launch its generative AI services in the country by integrating models from Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU).

Wipro (NYSE:WIT) reported gross revenue of Rs 244.8 billion ($2,585.9 million) for the quarter ended June 30, 2026, marking a 1% increase compared to the previous quarter.

FingerMotion (NASDAQ:FNGR) reported Q1 fiscal 2027 revenue of $650,089, down 92%, and a shareholder-attributable net loss of $2.0 million.

Olenox Industries (NASDAQ:OLOX) reported that its CS Digital Ventures division produced approximately 14.92 Bitcoin during June 2026, operating at an average hashrate of 1.06 EH/s.

State Street (NYSE:STT) reported a 17% year-over-year increase in total fee revenue to $3.19 billion, supported by growth in both servicing and management fees.

Prologis (NYSE:PLD) reported strong second quarter 2026 results and raised its full-year guidance after signing over 67 million square feet of leases.

Bank7 Corp. (NASDAQ:BSVN) reported second-quarter 2026 net income of $8.35 million, compared to $11.11 million in the same period last year.

IQSTEL (NASDAQ:IQST) reported $207 million in preliminary first-half net revenue to demonstrate its ongoing 59 percent year-over-year growth.

Greenwich LifeSciences (NASDAQ:GLSI) said European regulators approved combined HLA enrollment across approximately 170–180 FLAMINGO-01 clinical sites.

Medicus Pharma (NASDAQ:MDCX) received central IRB approval and written FDA feedback for its optimized Phase 2 ANT-2111-02 clinical study.

Gibraltar Industries (NASDAQ:ROCK) completed a two-step divestiture of its Renewables business by selling its racking and foundations operations to Unirac.

Abbott (NYSE:ABT) reported second-quarter 2026 sales of $12.6 billion and an adjusted earnings of $1.31 per diluted share.

ManpowerGroup (NYSE:MAN) reported second-quarter 2026 revenues of $4.9 billion and net earnings of $53.5 million.

LCNB Corp. (NASDAQ:LCNB) reported a record second-quarter net income of $7.5 million and earnings of $0.53 per share for the three months ended June 30.

Moderna (NASDAQ:MRNA) dosed the first U.S. participant in its Phase 1 trial evaluating the mRNA-4200 cancer antigen therapy.

Main Street Capital (NYSE:MAIN) projected second-quarter distributable net investment income between $1.02 and $1.06 per share.

Horizon Aircraft (NASDAQ:HOVR) reported fiscal 2026 fourth-quarter results, highlighting a strengthened cash balance of $78.3 million.

Merck (NYSE:MRK) received FDA approval for Lipfendra 20 mg after a Phase 3 trial showed a 56% LDL-C reduction versus placebo.

U.S. Bancorp (NYSE:USB) reported Q1 2026 net revenue of $7.288 billion and diluted EPS of $1.18, exceeding the $1.14 analyst estimate.

Eli Lilly (NYSE:LLY) executed a definitive agreement to acquire AtaiBeckley (NASDAQ:ATAI) for a $2.8 billion upfront equity valuation.

AtaiBeckley (NASDAQ:ATAI) shares jumped about 50% after Bloomberg reported that Eli Lilly (NYSE:LLY) could acquire the psychedelic drug developer this week.